Oyster Point Pharma announces varenicline solution nasal spray for treatment of dry eye to be covered by key Medicare pharmacy benefit manager

Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.

Investigators find link between myopia, POAG risk

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

Sight Sciences releases long-term safety, efficacy data of standalone use of Omni surgical system in patients with open angle glaucoma

According to the company, a study shows the non-implantable minimally invasive glaucoma surgery effectively reduces IOP and reduces need for IOP-lowering medications in patients diagnosed with open-angle glaucoma.